Skip to content
Aperlena
Language:

Germany - Pharmaceuticals - Open-House Biosimilar Discount Agreements 2025-29 - Omalizumab

Original Deutschland - Arzneimittel - Open-House-Biologika-Rabattverträge 2025-29 - Omalizumab

Open Contract notice 401 days left
Watch this tender

Deadline 31 Oct. If it moves, an email when the register sees it. A correction: the same email. Your plan: decide by 17 Oct, questions by 18 Oct, draft by 25 Oct. Log in

  1. Published
  2. Today
  3. Deadline open for 528 days
  4. Awarded pending

Summary

Machine-generated summary

German statutory health insurance funds are seeking discount agreements under Section 130a(8) SGB V for the active substance omalizumab, procured through an open-house biosimilar procedure. No individual negotiations take place; uniform conditions apply to all participants, and no exclusivity is granted to any contracting partner. Contracts run for a maximum of 24 months starting on 01.11.2025 and end no later than 31.10.2027 regardless of the signing date. Any suitable pharmaceutical entrepreneur may join by accepting the standard terms. Further details are provided in the participation and contract documents, which interested companies should consult before submitting.

Description

Die beteiligten Kassen verfolgen das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zu dem Wirkstoff Omalizumab zu schließen. Der Vertragsschluss erfolgt im Rahmen des Open-House-Biologika-Verfahrens der beteiligten Kassen: Individuelle Verhandlungen über Vertragsinhalte werden nicht geführt, es gelten einheitliche Konditionen. Die beteiligten Krankenkassen sichern einzelnen Vertragspartnern keine Exklusivität zu. Die Vertragslaufzeit beträgt maximal 24 Monate beginnend mit dem 01.11.2025. Der Vertrag endet spätestens am 31.10.2027, unabhängig vom Datum des Vertragsschlusses. Alle weiteren Informationen sind den Teilnahme- und Vertragsunterlagen zu entnehmen. Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Omalizumab im Rahmen eines Open-House-Verfahrens.

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 1 month ago

View the official notice

More from this buyer

Full buyer profile

7 open tenders right now

This buyer has no award history in this sector yet. Usual winners, Medical equipment & pharmaceuticals - Germany

Company Wins Total awarded Last win
Siemens Healthineers AG 42 €17.4M Sep 2026
Philips GmbH 20 €5.3M Sep 2026
GlaxoSmithKline GmbH & Co. KG 15 n/a Sep 2026
ASTRAZENECA GMBH 12 n/a Jul 2026
Brainlab Sales GmbH 10 €4.0M Sep 2026

Based on 1018 awards with a linked company profile over the last 2 years.

Change history

Every time an official source republished this notice with different content. We watch every source we index, including regional copies of the same notice.

  1. Act now
    • Submission deadline: Moved 1 day EARLIER: now October 31, 2027, 00:00
    • Scope and criteria: The description was expanded. Re-read it before you bid.

Follow this tender and we email you the moment it changes. Create account

Similar tenders

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€10,224,680
9,666 open across Europe right now
Buyer track record on Aperlena
8 notices tracked · 0 awarded

Never miss a tender like this

76 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

401 days left

Source

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Jump to the search box
?
Show these shortcuts
Esc
Close